Our story

The natural evolution of insulin delivery

For decades, insulin pen technology has transformed diabetes care. Yet, more than 20 million people worldwide still inject insulin with syringes.

When GO-Pen's co-founders looked at this gap, they saw an engineering opportunity: combine proven pen technology with insulin from vials.

That is how GO-PEN® was born. To us, this isn't about reinventing insulin delivery. It is about bringing the benefits of pen-based delivery to a large, underserved group of insulin users.

Why this hasn't been solved before

The obstacle hasn't been technology. It has been focus. Much of diabetes innovation has focused on increasingly advanced solutions and premium segments. Meanwhile, a large population continue to administer insulin from vials using syringes.

GO-PEN addresses this gap with a reusable insulin pen for vials, built for broader access and commercial scale.

Driven by purpose

GO-Pen is founded on a purpose of creating equal access to quality diabetes.

Our vision is a world where people using insulin from vials have access to insulin pens.

Our mission is to make GO-PEN® widely available by combining intuitive design, accurate dosing and reliable performance in a reusable insulin pen built for broader access and commercial scale.

GO-PEN has moved from an idea to a regulated medical device. With FDA 510(k) clearance and CE marking achieved, and usability testing completed with insulin users, the company is now moving towards commercialisation and scale.

Responsibility

We aim to balance environmental and social impact by creating equal access to quality diabetes care while minimizing environmental impact through evidence-based design and continuous optimization.

This is reflected in the decisions we make about design, production and distribution of our product. Our approach to sustainability stands on the three solid ESG pillars:

Environmental stewardship
Social impact
Responsible governance

Environmental stewardship

73% lower carbon footprint

GO-PEN® generates 8,97 kg CO2-eq compared to 33.10 kg CO2-eq for single-use syringes per functional unit.*

Before moving into large-scale production, we proactively partnered with DTU, the Danish Technical University, to conduct a comprehensive Life Cycle Assessment following ISO 14040/44 standards. This upfront analysis allows us to integrate environmental considerations into our planning and decision-making from the outset.

The LCA compared GO-PEN® against 1.0 mL single-use syringes across the complete product lifecycle, assessing 1,460 insulin injections - equivalent to one year of treatment with four daily injections - delivered in Denmark. The results demonstrate that GO-PEN® has a 73% lower carbon footprint compared to syringes.

By identifying environmental hotspots early in our development process, we can scale production while maintaining our commitment to both patient care and planetary stewardship.

With one pen lasting up to three years and a 73% lower carbon footprint compared to syringes, we're proving that quality healthcare and environmental stewardship can work hand in hand.

Significant Plastic Reduction One 3-year GO-PEN® eliminates the need for thousands of disposable syringes. Each GO-PEN® reservoir contains the same amount of insulin as 21 individual syringes, dramatically reducing plastic waste.

*Important context: The LCA assumes single-use practice for syringes as per Danish healthcare standards. In many low- and middle-income countries, economic constraints lead to syringe reuse, which may affect comparative environmental impact, though GO-PEN®'s fundamental sustainability benefits remain significant.

Social impact

GO-Pen is not just building a product; we are building a movement toward greater health equity in diabetes care. By combining vial insulin with a reusable pen platform, GO-PEN® is helping address a long-standing gap in insulin delivery.

Responsible governance

Our team's combined experience in diabetes care, regulatory excellence, and sustainable business practices guides our decision-making. We consider long-term impact on people, healthcare systems, and environmental outcomes in everything we do.

GO-PEN® aligns with the UN Sustainable Development Goals with a particular focus on:

SDG 3: Good Health and Well-being
SDG 8: Decent Work and Economic Growth
SDG 9: Industry, Innovation and Infrastructure
SDG 10: Reduced Inequalities
SDG 12: Responsible Consumption and Production

Our story

The natural evolution of insulin delivery

For decades, insulin pen technology has transformed diabetes care. Yet, more than 20 million people worldwide still inject insulin with syringes.

When GO-Pen's co-founders looked at this gap, they saw an engineering opportunity: combine proven pen technology with insulin from vials.

That is how GO-PEN® was born. To us, this isn't about reinventing insulin delivery. It is about bringing the benefits of pen-based delivery to a large, underserved group of insulin users.

Why this hasn't been solved before

The obstacle hasn't been technology. It has been focus. Much of diabetes innovation has focused on increasingly advanced solutions and premium segments. Meanwhile, a large population continue to administer insulin from vials using syringes.

GO-PEN addresses this gap with a reusable insulin pen for vials, built for broader access and commercial scale.

Driven by purpose

GO-Pen is founded on a purpose of creating equal access to quality diabetes.

Our vision is a world where people using insulin from vials have access to insulin pens.

Our mission is to make GO-PEN® widely available by combining intuitive design, accurate dosing and reliable performance in a reusable insulin pen built for broader access and commercial scale.

GO-PEN has moved from an idea to a regulated medical device. With FDA 510(k) clearance and CE marking achieved, and usability testing completed with insulin users, the company is now moving towards commercialisation and scale.

Responsibility

We aim to balance environmental and social impact by creating equal access to quality diabetes care while minimizing environmental impact through evidence-based design and continuous optimization.

This is reflected in the decisions we make about design, production and distribution of our product. Our approach to sustainability stands on the three solid ESG pillars:

Environmental stewardship

Social impact

Responsible governance

Environmental stewardship

73% lower carbon footprint

GO-PEN® generates 8,97 kg CO2-eq compared to 33.10 kg CO2-eq for single-use syringes per functional unit.*

By identifying environmental hotspots early in our development process, we can scale production while maintaining our commitment to both patient care and planetary stewardship.

With one pen lasting up to three years and a 73% lower carbon footprint compared to syringes, we're proving that quality healthcare and environmental stewardship can work hand in hand.

Significant Plastic Reduction One 3-year GO-PEN® eliminates the need for thousands of disposable syringes. Each GO-PEN® reservoir contains the same amount of insulin as 21 individual syringes, dramatically reducing plastic waste.

Social impact

GO-Pen is not just building a product; we are building a movement toward greater health equity in diabetes care. By combining vial insulin with a reusable pen platform, GO-PEN® is helping address a long-standing gap in insulin delivery.

Responsible governance

Our team's combined experience in diabetes care, regulatory excellence, and sustainable business practices guides our decision-making. We consider long-term impact on people, healthcare systems, and environmental outcomes in everything we do.

GO-PEN® aligns with the UN Sustainable Development Goals with a particular focus on:

SDG 3: Good Health and Well-being

SDG 8: Decent Work and Economic Growth

SDG 9: Industry, Innovation and Infrastructure

SDG 10: Reduced Inequalities

SDG 12: Responsible Consumption and Production